TP53 and cancer: Overall, the crosstalk between p53-mutant cancer cells and the tumor microenvironment, particularly involving myeloid cells and Treg cells, creates a conducive immunosuppressive niche that promotes tumor growth, invasion, and resistance to immunotherapy.